Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 15/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 13/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 13/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.41 |
| ▸ | OGA | O60502 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7469677 | 0.85 | ADRB1 (0.46) | ADRB3ADRB1ADRB2HRH3LMNA | |
| SCHEMBL6953322 | 0.84 | HRH3 (0.44) | ADRB3ADRB1ADRB2HRH3LMNA | |
| SCHEMBL7469004 | 0.83 | ADRB3 (0.52) | ADRB3ADRB1ADRB2HRH3LMNA | |
| SCHEMBL7473044 | 0.83 | ADRB3 (0.52) | ADRB3ADRB1ADRB2HRH3LMNA | |
| SCHEMBL7467963 | 0.83 | LMNA (0.44) | ADRB3ADRB1ADRB2HRH3LMNA | |
| SCHEMBL7458989 | 0.83 | HRH3 (0.43) | ADRB3ADRB1ADRB2HRH3LMNA | |
| SCHEMBL7560376 | 0.80 | LMNA (0.56) | ADRB3ADRB1ADRB2HRH3LMNA | |
| SCHEMBL6301392 | 0.80 | HRH3 (0.47) | ADRB3ADRB1ADRB2HRH3LMNA | |
| SCHEMBL7470650 | 0.76 | LMNA (0.46) | ADRB3ADRB1ADRB2HRH3LMNA | |
| SCHEMBL7461831 | 0.76 | LMNA (0.46) | ADRB3ADRB1ADRB2HRH3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6649627-B1 | N-Substituted with 1- (pyrid-2-yl)-piperidine-4-yl radical; gastrointestinal and psychological disorder treatment; antidiabetic tocolytic, and antidepressant agents; irritable bowel syndrome, glaucoma and dysmenorrhoea | SANOFI-SYNTHELABO (FR) | 2003-11-18 | — | — | US | disclosed |